Actimmune oncology program ends
This article was originally published in Pharmaceutical Approvals Monthly
InterMune is discontinuing its oncology program for its biologic response modifier Actimmune (interferon gamma-1b) following negative results from a Phase III ovarian cancer trial, the firm says Feb. 2. The firm halted the GRACES trial in advanced ovarian cancer after Actimmune plus carboplatin and paclitaxel showed a significantly shorter overall survival than the two cytotoxic agents alone (39.7% vs. 30.4%, respectively; p=0.001). "The results from this study suggest that Actimmune…may exacerbate the dose-limiting toxicities of cytotoxic chemotherapy drugs. Consequently, we have no plans to initiate further studies of Actimmune in oncology or in combination with such chemotherapy regimens," InterMune said. Actimmune is indicated for chronic granulomatous disease and severe, malignant osteopetrosis...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”